Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2025)
Historic Cost of Revenue for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $49000.0.
- Orchestra BioMed Holdings' Cost of Revenue fell 2794.12% to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $197000.0, marking a year-over-year increase of 207.25%. This contributed to the annual value of $204000.0 for FY2024, which is 967.74% up from last year.
- As of Q3 2025, Orchestra BioMed Holdings' Cost of Revenue stood at $49000.0, which was down 2794.12% from $46000.0 recorded in Q2 2025.
- Orchestra BioMed Holdings' 5-year Cost of Revenue high stood at $68000.0 for Q3 2024, and its period low was $34000.0 during Q1 2024.
- Over the past 4 years, Orchestra BioMed Holdings' median Cost of Revenue value was $47000.0 (recorded in 2023), while the average stood at $49333.3.
- Its Cost of Revenue has fluctuated over the past 5 years, first soared by 6585.37% in 2024, then plummeted by 2794.12% in 2025.
- Over the past 4 years, Orchestra BioMed Holdings' Cost of Revenue (Quarter) stood at $53000.0 in 2022, then decreased by 11.32% to $47000.0 in 2023, then rose by 23.4% to $58000.0 in 2024, then decreased by 15.52% to $49000.0 in 2025.
- Its last three reported values are $49000.0 in Q3 2025, $46000.0 for Q2 2025, and $44000.0 during Q1 2025.